NewcelX (NCEL) Stock Forecast: StockMap's 2-Week Call
NCEL stock forecast: StockMap's model calls NewcelX Strong Underperform for the two weeks after the Nov 19 close: it expects NCEL to trail the growth index. It is a call on the gap, not a price target. Right in 3 of 6 two-week windows on NCEL since Aug 21; by chance, a call on the same dates was right 59% of the time.
NewcelX last closed at $2.69, +1.51% on the session.
Against the IVW growth benchmark the position is +3.84% over the forecast window.
NewcelX's market cap is $14.48M as of November 19, 2026.
Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -90 (behind).
Where NCEL sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 0 bullish and 15 bearish.
Agreement across those insights is 100%.
49 daily calls for NCEL so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
NewcelX is classified under Health Care / Biotechnology.
StockMap tracks NewcelX as the 347th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite NewcelX ranks 394th of 394 in the group, against a group median of -0.27.